Guobang Pharma Ltd (605507) - Total Assets
Based on the latest financial reports, Guobang Pharma Ltd (605507) holds total assets worth CN¥10.58 Billion CNY (≈ $1.55 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Guobang Pharma Ltd (605507) net assets for net asset value and shareholders' equity analysis.
Guobang Pharma Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Guobang Pharma Ltd's total assets have evolved over time, based on quarterly financial data.
Guobang Pharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guobang Pharma Ltd's total assets of CN¥10.58 Billion consist of 54.5% current assets and 45.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.7% |
| Accounts Receivable | CN¥1.35 Billion | 12.5% |
| Inventory | CN¥1.36 Billion | 12.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥350.83 Million | 3.3% |
| Goodwill | CN¥25.49K | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Guobang Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 605507 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guobang Pharma Ltd's current assets represent 54.5% of total assets in 2024, a decrease from 60.3% in 2017.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2024, down from 23.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 12.7% of total assets.
Guobang Pharma Ltd Competitors by Total Assets
Key competitors of Guobang Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Guobang Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 2.21 | 1.46 |
| Quick Ratio | 2.30 | 1.70 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.96 Billion | CN¥3.10 Billion | CN¥898.70 Million |
Guobang Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between Guobang Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.93 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | CN¥10.78 Billion |
| Market Capitalization | $1.92 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guobang Pharma Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guobang Pharma Ltd's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guobang Pharma Ltd (2017–2024)
The table below shows the annual total assets of Guobang Pharma Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.78 Billion ≈ $1.58 Billion |
+4.04% |
| 2023-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
+14.58% |
| 2022-12-31 | CN¥9.04 Billion ≈ $1.32 Billion |
+20.37% |
| 2021-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
+36.39% |
| 2020-12-31 | CN¥5.51 Billion ≈ $806.08 Million |
+15.74% |
| 2019-12-31 | CN¥4.76 Billion ≈ $696.45 Million |
+8.99% |
| 2018-12-31 | CN¥4.37 Billion ≈ $638.98 Million |
+8.51% |
| 2017-12-31 | CN¥4.02 Billion ≈ $588.86 Million |
-- |
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more